NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Bima Life Sciences

Shanghai Bima Life Sciences

Private
ShanghaiHealthcare & Life Scienceshttps://bimalifesciences.com

Last Round

Series B

Jan 4, 2022

Est. Valuation

$30.8M

Total Funding Raised

$50M

Company Overview

Shanghai Bima Life Sciences is a biotechnology company that provides a proteomics detection platform based on antibody affinity assay.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

contract research organizationCROpreclinical researchdrug discoverytoxicology servicespharmacologypharmacokineticsPK/PDproteomicsbioinformaticsin vivo testingin vitro testinglab servicesoutsourced R&Dbiotech services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Bima Life Sciences Comparables

Compare Shanghai Bima Life Sciences with similar companies based on industry and business-model similarity.

Shanghai Bima Life Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TriApex Laboratories
81%
Prisys Biotechnology Co., Ltd.
81%
Shanghai Medicilon Inc.
81%

Shanghai Bima Life Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 4, 2022
Series A ExtensionAug 7, 2020
Series AJan 1, 2019
AngelJun 1, 2017

Shanghai Bima Life Sciences Investors

Notable investors and investment history

Shanghai Bima Life Sciences investors
InvestorRounds
Photon FundSeries B
Sincere CapitalSeries B
Highlight CapitalSeries B
Kaitai CapitalSeries A Extension, Series A
J-One Capital InvestSeries A Extension
Shengshan Asset ManagementSeries A
Viva BiotechSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 4, 2022

    $30M round led by Highlight Capital and Photon Fund.

  • Jun 1, 2017

    Completed an Angel round of funding.

Shanghai Bima Life Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Bima Life Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Bima Life Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year FoundedN/A
Last FundingJan 4, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.